Bottom Line: LIG still faces uphill battle
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.YOU WOULD have to be very brave to buy shares just now in London International Group, even after the company has finally bitten the bullet on ColourCare.
Photoprocessing and condoms never had any synergy. The decision to diversify the Durex manufacturer into the holiday snaps business was an opportunistic move that went horribly wrong.
The new management has been right to recognise that the only course of action was to get out of the ColourCare business as quickly and cheaply as it could.
The disposal of almost all of ColourCare is very costly, but it means LIG can now concentrate on its core gloves and condoms business and begin work on its devastated finances.
But from here it will still be an uphill battle. LIG acknowledges that the condoms and examination gloves market has become a low growth, low cost, high volume sales business where the competition from rubber-producing countries such as Malaysia is stiffer by the day.
The group sees its salvation in strong brand names such as Durex - especially important in emerging markets like Eastern Europe - and high-tech surgeons' gloves that are beyond the competence of low cost producers.
With debts estimated at pounds 160m- pounds 200m and net assets that will be almost wiped out by this year's losses, LIG's balance sheet looks very sick. The refinancing expected next month - probably a two-for-three rights issue at about pounds 1 a share to raise pounds 100m - will barely be enough to put it back on its feet.
For all but the most risk-tolerant investors the shares at 116p are still to be shunned.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments